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Introduction: Heart failure places a signiﬁcant economic burden on health care. Acute heart failure requires hos-
pitalization and often frequent re-hospitalization in expensive wards where vasoactive rescue therapy is often
added on top of standard medications.
In these lean times, there is a growing need for cost-effective therapeutic options that supply superior support
and in addition shorten the length of stay in hospital and reduce re-hospitalization rates. The inodilator
levosimendan represents the latest addition to the vasoactive treatments of acute heart failure patients, and it ap-
pears to meet these expectations.
Our aimwas to answer the questionwhether the treatment efﬁcacy of levosimendan –when selected as therapy
for patients hospitalized for acute heart failure – brings savings to hospitals in various European countries
representing different economies.
Methods and results:We took a conservative approach and selected some a fortiori arguments to simplify the cal-
culations.We selected seven European countries to represent different economies: Italy, Spain, Greece, Germany,
Sweden, Finland and Israel. Data on the costs of medications and on the cost per day were collected and fed in a
simple algorithm to detect savings. These saving varied from country to country, from a minimum of €0.50 in
Germany to a maximum of €354.64 in Sweden.
Conclusions: The use of levosimendan as a therapy for patients hospitalized for acute heart failure provides a net
saving to hospitals driven by a reduction in the length of hospital stay. This ﬁnding is true in each of the countries
considered in this study.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Heart failure places a signiﬁcant economic burden on society and
health care system. In Western countries, direct medical costs of heart
failure comprise 1% to 2% of overall health expenditure [1]. Two thirds
of these disbursals are attributable to frequent and repetitive hospitali-
zation due to episodes of cardiac decompensation [2,3]. This implies the
need for cost-effective therapeutic options that shorten the length ofUniversity of Helsinki Central
en).
d Ltd. This is an open access article uhospital stay, and reduce re-hospitalization rates and in-hospital
mortality.
The inodilator levosimendan appears tomeet these expectations [4].
Its pharmacological effects include increased cardiac contractility,
achieved without increased oxygen consumption, combined with vaso-
dilation [5], which is often considered a suitable pharmacological
strategy in acute heart failurewhen patients are ‘wet and cold’ [6]. In ad-
dition to these haemodynamic clinical improvements [7], levosimendan
also enhances renal function [8,9] and was shown to have positive ef-
fects on survival [10–14]. Furthermore, a greater proportion of days
spent alive and outside hospital [11] and shorter hospital stay [14–16]
is achieved for levosimendan-treated patients compared to those who
receive dobutamine or placebo.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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been previously addressed in studies that have described both cost-
effectiveness and cost-reduction, using different well-established
pharmaco-economic methods [4,16–20]. One of these was an evalua-
tion by Lucioni et al. [4] that was based on a retrospective study
conducted in patients with acute HF, who had been treated with ei-
ther levosimendan (n = 147) or dobutamine (n = 145) at a teaching
hospital in Rome. Compared to dobutamine, the administration of
levosimendan signiﬁcantly reduced the mean length of hospital stay
(LOS) by 1.5 days, decreased the re-hospitalization rate by 6.7%, and
the 1-month mortality rate by 4.8%. These data are in keeping with
the data obtained in clinical trials on levosimendan [10,11,15,21,22],
as well as in a meta-analysis [14].
Lucioni et al. [4] assessed the comparative hospital costs and savings
of alternative treatments from the perspective of the payer, and com-
pared the cost difference between the use of levosimendan and dobuta-
mine with the analogous savings difference. The authors reasoned that
hospitals might not be inclined to choose levosimendan because of its
relatively high acquisition cost, but if the additional expense was offset
by savings due to superior efﬁcacy over other treatments, the situation
might be different. The authors concluded that levosimendan appears
to be a competitive alternative compared with dobutamine for the
treatment of acute heart failure in the Italian hospital setting. The
costs of hospitalization, however, vary from country to country.
A meeting of experts was held in Seville, Spain, on May 25, 2015,
aimed at assessing the European perspective beyond the scope of the
data of Lucioni et al. [4]. The panel set out to compare the results previ-
ously obtained in Italy, with similar data obtained in six other European
countries: Spain, Greece, Germany, Sweden, Finland and Israel. The aim
was to shed light on the overall pharmaco-economic consequences aris-
ing from the use of levosimendan for patients with acute heart failure
and advanced heart failure with frequent hospitalization.
2. Methods
2.1. Type of economic analysis
This evaluation was conducted as a cost–beneﬁt analysis (rather than a cost-minimi-
zation analysis, as the competing treatments considered here do not have the same efﬁca-
cy). In this approach, the comparative costs and beneﬁts (in terms of savings) of
alternative treatments were analyzed from the perspective of the payer [23]. This analysis
did not take into account the beneﬁts of levosimendan for the improvement of patients
symptoms and for the reduction of patient mortality versus the comparators, as those
data are described elsewhere (for review, see Nieminen et al. [6]). Instead, the approach
used here allows the payer to assess the cost impact of levosimendan treatment. The eco-
nomic evaluation was performed from the hospital perspective, through a comparison of
the hospital costs for the use of levosimendan versus other treatments in the cardiology
setting.
2.2. Selected countries
Seven European countries were selected to represent different European economies:
Italy, Spain, Greece, Germany, Sweden, Finland and Israel. Data were collected on the costs
per day for the hospital wards and on the costs of therapies in those countries.
2.3. Cost savings for hospitals
Considering the drug costs only, a hospital might not be inclined to choose
levosimendan, because of its relatively high acquisition cost. However, the situation
might be different if proven that the incremental drug cost is offset by the savings from
the improved treatment effectiveness of the drug compared to other treatments, particu-
larly relating to the shorter hospitalization. Such savings would thus be in the form of cost
reduction from length of stay (LOS) reductions.
In reimbursement systems based on diagnosis-related groups (DRGs), the reimburse-
ment to the hospital is ﬁxed (up to a point), and includes also costs for the patient ward
care length, calculated from an average LOS. In case the patient is discharged in advance
compared to the reference LOS, the system generates a gain for the hospital, while
prolonged hospitalization makes a net loss. This is however not true with regard to
some costs, such as the hospital overheads and medical staff, as these are not directly
linked to the LOS.
Ideally, savings on the variable costs due to a LOS reduction should be measured on
the basis of the average variable cost per day of a hospital stay (including drugs, subsidiary
procedures, diagnostic tests, etc.), herewith reference to a CardiologyDepartment. For thesake of precision, it should be noted that an average value would overestimate the correct
value, due to the right-skewed distribution of the variable cost as a function of the in-
patient stay time [18].
2.4. The assumptions
To simplify the model, we make some assumptions that are intended to be a fortiori
arguments i.e. from yet stronger reasons. For example we set the effect of levosimendan
on re-hospitalization rate as null, the effect of levosimendan on co-morbidities affecting
hospital costs as null, and the effect of levosimendan on mortality as null. We intend to
demonstrate in the following paragraphs that these assumptions can be used as argu-
ments a fortiori as they are all conservative and exceeded by the data in the literature.
2.4.1. Cost of comparator treatment
We assume that the costs of the comparators (usually dobutamine, but in some case
milrinone, enoximone, etc.) are as low as €30 per treatment. This sum was obtained by
ﬁnding the lowest retail discounted price for an inotropic support treatment with the
cheapest generic (dobutamine) within the seven countries considered in this study. As,
in reality, these treatments do have a higher cost in all the other countries and in the ma-
jority of the hospitals, this is a valid a fortiori argument in the model. As a comparison,
Cleland et al. [17] calculated – on the basis of the clinical trial LIDO and on the average
prices in Denmark, Finland, France, Germany, The Netherlands, Norway, Sweden and the
UK in year 2000 – that the cost of 24 hour treatment with dobutamine was €41.30
(i.e. 700 mg × 0.059 €/mg).
2.4.2. Overall cost of drugs
In the literature, it has been reported that the use of levosimendan in cardiology
settings is associated with less use of rescue pharmacological treatments [15]. Again, for
the sake of simplicity, in our model we assume that the overall difference in costs of the
drugs (apart from levosimendan) for patients treatedwith levosimendan versus the com-
parator is null. This assumption is valid more so in cases when levosimendan is used on
top of standard of care. For all of these reasons above we consider also this a valid a fortiori
argument.
2.4.3. Re-hospitalization rate
Data obtained from the literature show that the use of levosimendan is associated
with a reduction in re-hospitalization rates [11,20]. Thus, further savingsmight be derived
in the heart failure patient care chain from this improved effectiveness of levosimendan,
as shown by Lucioni et al. [4] However, this postulate remains fully valid only as far as a
full occupancy assumption can be made for the beds in a Cardiology Department,
whereas without a full bed occupancy situation, new admissions would not need to com-
pete for beds. In the absence of a national average value of bed occupancy in the cardiology
setting for acute heart failure hospitalization, we believe that considering the effect of
levosimendan treatment on re-hospitalization as null is a useful and justiﬁed a fortiori
argument.
2.4.4. Effects on co-morbidities that affect hospital costs
Data obtained from the literature show that the use of levosimendan is associated
with a reduction in serious adverse events and comorbidities (e.g. cardiac failure [12],
and renal complications [9]) that affect hospital costs. Thus, considering the effects of
levosimendan treatment on this parameter as null is also a useful and justiﬁed a fortiori
argument.
2.4.5. Variations in the costs of ‘a day in hospital’
The costs of a ‘day in hospital’ vary with the level of the ward, from several thousand
euros per daywhen an acute patient is treated in the intensive settings of a Cardiac Critical
Care Unit, to some hundreds of euros per day when the patient is transferred to a cardiac
ward at the end of his/her stay. Indeed, levosimendan is used during the acute phase, but
many reports fail to show clear distinctions between the days spent in intensive cardiac
units (more expensive) and the days spent in the post-acute cardiac wards (less expen-
sive). In our calculation, we thus consider the costs of a ‘day in hospital’ in the cardiac
ward (Table 1) as if all of the LOS beneﬁts would be obtained in the later and less expen-
sive phase of the hospital stay. We consider also this as a valid a fortiori argument.
2.5. The calculations
The analysis is an incremental type, with the comparison of the cost differences be-
tween two in-hospital therapies (levosimendan and the comparator, respectively) with
the respective savings differences. Costs and savings are referred to one patient/treatment
case. The outcome of the analysis can then be deﬁned as:
NS ¼ SL–CLð Þ ð1Þ
where
NS is the net savings
SL is the beneﬁt (savings) from using levosimendan versus the comparator
CL is the additional costs for using levosimendan versus the comparator.
Fig. 2. The composite parameter ‘days alive and out of hospital’ in a phase III regulatory
study of levosimendan vs. dobutamine (from Follath [11]). Levosimendan (gray), dobuta-
mine (black).
Table 1
Costs and savings of levosimendan treatment of patients hospitalized for acute heart
failure.
Country Costs (€) Net savings (€)
CLa Cardiac ward
(per day)b
By using
levosimendanc
Italy 648.86 416d −12.58
Spain 598.79 421e −70.60
Greece 487.07 361f −86.92
Germany 715.00 450g −0.50
Sweden 648.65 631h −354.64
Finland 659.18 450i −56.32
Israel 561.57 368j −23.55
aAdditional drug costs of a levosimendan treatment vs. comparator treatment calculated
according to the text; bexcluding the costs for levosimendan; cnet savings considering a re-
duction of 1.59 days of stay in the cardiac ward obtained by levosimendan treatment;
dcalculated from DRG 127 in the ICD9-CM DRG classiﬁcation [29]; ein 2013 according to
RECH [30]; fcalculated from the data by Parissis et al. [24]; gdata calculated from the
Fallpauschalen-Katalog for the relevant DRG codes (InEK 2014) [31]; haverage cardiac
ward cost at ‘Akademiska sjukhuset’, Uppsala, Sweden; ifrom HUS Palveluhinnasto 2015
[32]; jaccording to the Israeli Ministry of Health [33].
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For the treatment costs, the DRG 127 tariff is considered as a proxy for the costs borne
by a hospital for hospitalization of one patient with acute heart failure. This tariff is appli-
cable to all patients, regardless of the treatment that they will receive. As the cost of one
vial of levosimendan is not included in the DRG 127 tariff, we thus deﬁne CL as the cost
of one vial of levosimendan (which is the average dose for a single treatment) detracted
by an assumed price for treatment with comparator (see Section 2.4.1) of €30. The costs
for one vial of levosimendan were obtained from the local retailers that supply the hospi-
tals in the countries considered in this study. These prices were an average over the retail
prices in year 2014. All exchange rates, if the pricewasnot in Euro,were the one ofMay31,
2015.2.5.2. Beneﬁt (savings)
The savings (SL) corresponding to each discharge that occurs in advance (i.e. shorter
hospitalization) due to the use of levosimendan are evaluated by multiplying the LOS re-
duction, by the cost on one day in hospital.
SL ¼ ΔLOSL  daily hospital cost: ð2Þ
As already indicated, this additional revenue is not net. Indeed, only a part should be
taken into account corresponding to the variable costs, but this operation is particularly
demanding since the variable costs in a hospital department are very difﬁcult to estimate.
In the fortunate case of Greece we relied on the data presented by Parissis et al. [24] who
did calculate an average cost for AHF, an average LOS, and even indicated which percent-
age of the expenses were generated by ﬁxed and variable costs.Fig. 1. Levosimendan, on top of standard of care, shortened the hospital stay for patients
with acute heart failure in a phase III study vs. placebo (panel A, from de Lissavoy [16]),
and in a single center large registry study vs. dobutamine (panel B, from Fedele [20]).
Levosimendan (gray), dobutamine (black).2.6. The beneﬁts in length of hospital stay
Levosimendan, on top of standard of care, shortens hospital stays for patients with
acute heart failure. These data have been shown both in a phase III study (vs. placebo)
[16] and in a single center large registry study (vs. dobutamine) [20] (see Fig. 1).
An earlier phase III regulatory study corroborates these conclusions by showing that
the composite parameter ‘days alive and out of hospital’ was signiﬁcantly in favor of
levosimendan over dobutamine [11] (Fig. 2).
Finally, in a meta-analysis of the eight studies in which levosimendan was used in
cardiology settings which reported LOS data, the LOS was decreased by 1.59 days for the
levosimendan-treated patients in addition to a signiﬁcant reduction in mortality [14]
(Fig. 3).
For the sake of the present exercisewe thus considered that levosimendan,when used
in cardiology settings, shortens LOS by 1.59 days.
3. Results
We performed the calculations based on the algorithm and conser-
vative assumptions described above, and obtained the level of net
savings for the selected countries and for theward environment consid-
ered (Table 1). In all cases, the choice of levosimendanwas shown to be
dominant over comparators; i.e. there is a net saving from the hospital
perspective.
This saving varies from country to country, fromaminimumof €0.50
in Germany to a maximum of €354.64 in Sweden.
4. Discussion
The model which we used here is a very simple approximation
of a cost analysis. We intended to answer the question whether
levosimendan, sold at the current price, consistently brings savings to
hospitals in selected European countries when it is used as therapy for
patients hospitalized for acute heart failure. We did not aim to quantify
these savings, and therefore we used a fortiori arguments which by
deﬁnition simplify the calculations at the price of losing the real value
of the savings. Parameters such as the positive effects of levosimendan
on the costs of additional drugs, on re-hospitalization, and on co-
morbidity – which were neglected in our calculations – might have
increased the savings ﬁgures. Similarly, we assumed that the reduction
in LOS associated with the use of levosimendan was not due to less
days spent in intensive cardiac units (more expensive) but to less days
spent in the post-acute cardiac wards (less expensive). Indeed, a sign
that levosimendan reduces also the LOS in intensive cardiac unit was
seen in the regulatory Phase III study REVIVE [16]: in the levosimendan
study arm the patients left the ICU 0.348 days earlier (p= 0.63) than in
the control group (placebo on top of standard of care). Since the cost of
one day in ICU varies between €1000 and €2500 in the European coun-
tries under scrutiny in this paper, this would lead to amuch positive cal-
culation of hospital savings of several hundred euros. In fact, according
to the pharmaco-economic analysis of the REVIVE study (performed in
the U.S.A. between 2003 and 2005 [15,16]), the cost differential favoring
levosimendan was about $1800 (P = 0.01) for the sub-set correspond-
ing to current labeling (patients with SBP ≥ 100 mm Hg).
Finally, data obtained from the literature show that the use of
levosimendan in cardiology settings is associated with both an
Fig. 3. Length of stay in hospital from a meta-analysis of eight studies of levosimendan in cardiology settings (adapted from Landoni [14]). WMD, weighted mean difference. Weights
are from random effect analysis. The studies listed in the Forrest plot refer to the following publications: Berg 2010 [34], Duygu 2008a [35], Duygu 2008b [36], Follath 2002 [11], Mebazaa
2007 [22], Packer 2013 [15], Parissis 2007 [37], Trikas 2006 [38].
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mortality [14], which provides even stronger support for the rationale
of using the drug.
An important limitation of this study is that in the countries selected
for this exercise the hospital costs for acute heart failure are not avail-
able in the same form; sometimes they include the costs of drugs and di-
agnosis, sometimes not. A more exact calculation is warranted when
such exact data on ﬁxed and variable costs of hospitalization will be
available for all countries.
Levosimendan is the ‘ﬁrst in class’ of the calcium sensitizer and po-
tassium channel opener family, and its current clinical development
aims to take this treatment beyond the ﬁeld of acute decompensated
heart failure. It was demonstrated that levosimendan decreases infarct
size in ischemia-reperfusion models [26] and improves survival in
healed myocardial infarction models [27], and many clinical trials
have followed to test the effects of this drug in cardiac surgery [28]. It
should be noticed, however, that the present pharmaco-economic cal-
culations were focused exclusively on the use of levosimendan in cardi-
ac settings and cannot be applied directly to other settings, where both
the costs and the effects of levosimendan will be most probably differ-
ent. A separate analysis in those settings would be of great interest
and is warranted.
5. Conclusions
The use of levosimendan for patients hospitalized for acute heart
failure brings net savings to hospitals primarily due to the consistent re-
duction in LOS. Furthermore, these savings are gained in all of the
European countries considered in the present study.
Author contributions
Three of the authors (MSN, MK, PP) independently performed the
preliminary search for relevant publications. All of the authors contrib-
uted substantially to discussions of the existing literature, the costs and
beneﬁts, and the validity of the model. All of the authors, moreover,
reviewed the manuscript before submission.
Conﬂict of interest
This project did not receive any ﬁnancial support. PP andMKare em-
ployees of Orion Pharma. The other authors do not declare any conﬂict
of interest.Acknowledgments
We thank Dr. Judith Moser and Dr. Christopher Berrie for editing of
the manuscript.References
[1] C. Berry, D.R. Murdoch, J.J. McMurray, Economics of chronic heart failure, Eur. J.
Heart Fail. 3 (2001) 283–291.
[2] T. Rydén-Bergsten, F. Andersson, The health care costs of heart failure in Sweden, J.
Intern. Med. 246 (3) (1999) 275–284.
[3] S. Stewart, A. Jenkins, S. Buchan, A. McGuire, S. Capewell, J.J. McMurray, The current
cost of heart failure to the National Health Service in the UK, Eur. J. Heart Fail. 4 (3)
(2002) 361–371.
[4] C. Lucioni, A. D'Ambrosi, S. Mazzi, P. Pollesello, M. Apajasalo, F. Fedele, Economic
evaluation of levosimendan versus dobutamine for the treatment of acute heart fail-
ure in Italy, Adv. Ther. 29 (12) (2012) 1037–1050.
[5] Z. Papp, I. Édes, S. Fruhwald, S.G. De Hert, M. Salmenperä, H. Leppikangas, A.
Mebazaa, G. Landoni, E. Grossini, P. Caimmi, A. Morelli, F. Guarracino, R.H.
Schwinger, S. Meyer, L. Algotsson, B.G. Wikström, K. Jörgensen, G. Filippatos, J.T.
Parissis, M.J. González, A. Parkhomenko, M.B. Yilmaz, M. Kivikko, P. Pollesello, F.
Follath, Levosimendan: molecular mechanisms and clinical implications: consensus
of experts on the mechanisms of action of levosimendan, Int. J. Cardiol. 159 (2)
(2012) 82–782.
[6] M.S. Nieminen, S. Fruhwald, L.M. Heunks, P.K. Suominen, A.C. Gordon, M. Kivikko, P.
Pollesello, Levosimendan: current data, clinical use and future development, Heart
Lung Vessel 5 (4) (2013) 227–245.
[7] M.S. Nieminen, J. Akkila, G. Hasenfuss, F.X. Kleber, L.A. Lehtonen, V. Mitrovic, O.
Nyquist, W.J. Remme, Hemodynamic and neurohumoral effects of continuous infu-
sion of levosimendan in patients with congestive heart failure, J. Am. Coll. Cardiol.
36 (6) (2000) 1903–1912.
[8] Z.Q. Hou, Z.X. Sun, C.Y. Su, H. Tan, X. Zhong, B. Hu, Y. Zhou, D.Y. Shang, Effect of
levosimendan on estimated glomerular ﬁltration rate in hospitalized patients with de-
compensated heart failure and renal dysfunction, Cardiovasc. Ther. 31 (2013) 108–114.
[9] M.B. Yilmaz, E. Grossini, J.C. Silva Cardoso, I. Édes, F. Fedele, P. Pollesello, M. Kivikko,
V.P. Harjola, J. Hasslacher, A. Mebazaa, A. Morelli, J. le Noble, A. Oldner, I. Oulego
Erroz, J.T. Parissis, A. Parkhomenko, G. Poelzl, S. Rehberg, S.E. Ricksten, L.M.
Rodríguez Fernández, M. Salmenperä, M. Singer, S. Treskatsch, B. Vrtovec, G.
Wikström, Renal effects of levosimendan: a consensus report, Cardiovasc. Drugs
Ther. 27 (6) (2013) 581–590.
[10] V.S. Moiseyev, P. Pöder, N. Andrejevs, M.Y. Ruda, A.P. Golikov, L.B. Lazebnik, Z.D.
Kobalava, L.A. Lehtonen, T. Laine,M.S. Nieminen, K.I. Lie, RUSSLAN Study Investigators.
Safety and efﬁcacy of a novel calcium sensitizer, levosimendan, in patients with left
ventricular failure due to an acute myocardial infarction. A randomized, placebo-
controlled, double-blind study (RUSSLAN), Eur. Heart J. 23 (2009) 1422–1432.
[11] F. Follath, J.G. Cleland, H. Just, J.G. Papp, H. Scholz, K. Peuhkurinen, V.P. Harjola, V.
Mitrovic, M. Abdalla, E.P. Sandell, L. Lehtonen, Steering Committee and Investigators
of the Levosimendan Infusion versus Dobutamine (LIDO) Study. Efﬁcacy and safety
of intravenous levosimendan compared with dobutamine in severe low-output
heart failure (the LIDO study): a randomised double-blind trial, Lancet 360 (9328)
(2002) 196–202.
[12] A. Mebazaa, M.S. Nieminen, G.S. Filippatos, J.G. Cleland, J.E. Salon, R. Thakkar, R.J.
Padley, B. Huang, A. Cohen-Solal, Levosimendan vs. dobutamine: outcomes for
341M.S. Nieminen et al. / International Journal of Cardiology 199 (2015) 337–341acute heart failure patients on beta-blockers in SURVIVE, Eur. J. Heart Fail. 11 (2009)
304–311.
[13] A. Delaney, C. Bradford, J. McCaffrey, S.M. Bagshaw, R. Lee, Levosimendan for the
treatment of acute severe heart failure: a meta-analysis of randomised controlled
trials, Int. J. Cardiol. 138 (2010) 281–289.
[14] G. Landoni, G. Biondi-Zoccai, M. Greco, T. Greco, E. Bignami, A. Morelli, F. Guarracino,
A. Zangrillo, Effects of levosimendan on mortality and hospitalization. A meta-
analysis of randomized controlled studies, Crit. Care Med. 40 (2) (2012) 634–646.
[15] M. Packer, W. Colucci, L. Fisher, B.M. Massie, J.R. Teerlink, J. Young, R.J. Padley, R.
Thakkar, L. Delgado-Herrera, J. Salon, C. Garratt, B. Huang, T. Sarapohja, REVIVE
Heart Failure Study Group. Effect of levosimendan on the short-term clinical course
of patients with acutely decompensated heart failure, JACC Heart Fail 1 (2) (2013)
103–111.
[16] G. de Lissovoy, K. Fraeman, J.R. Teerlink, J. Mullahy, J. Salon, R. Sterz, A. Durtschi, R.J.
Padley, Hospital costs for treatment of acute heart failure: economic analysis of the
REVIVE II study, Eur. J. Health Econ. 11 (2010) 185–193.
[17] J.G. Cleland, A. Takala, M. Apajasalo, N. Zethraeus, G. Kobelt, Intravenous
levosimendan treatment is cost-effective compared with dobutamine in severe
low-output heart failure: an analysis based on the international LIDO trial, Eur. J.
Heart Fail. 5 (1) (2003) 101–108.
[18] M.T. Oliveira Jr., W. Follador, M.L. Martins, et al., Cost analysis of the treatment of
acute decompensated heart failure. Levosimendan versus dobutamine, Arq. Bras.
Cardiol. 85 (2005) 9–14.
[19] G. de Lissovoy, K. Fraeman, J. Salon, T. ChayWoodward, R. Sterz, The costs of treating
acute heart failure: an economic analysis of the SURVIVE trial, J. Med. Econ. 11
(2008) 415–429.
[20] F. Fedele, A. D'Ambrosi, N. Bruno, C. Caria, B. Brasolin, M. Mancane, Cost-
effectiveness of levosimendan in patients with acute heart failure, J. Cardiovasc.
Pharmacol. 58 (2011) 363–366.
[21] M. Zairis, C. Apostolatos, P. Anastasiadis, et al., The effect of a calcium sensitizer or an
inotrope or none in chronic low output decompensated heart failure: results from
the calcium sensitizer or inotrope or none in low output heart failure study (CASI-
NO), J. Am. Coll. Cardiol. 43 (5 Suppl. 1) (2004) A206–A207.
[22] A. Mebazaa, M.S. Nieminen, M. Packer, A. Cohen-Solal, F.X. Kleber, S.J. Pocock, R.
Thakkar, R.J. Padley, P. Põder, M. Kivikko, S.U.R.V.I.V.E. Investigators, Levosimendan
vs dobutamine for patients with acute decompensated heart failure: the SURVIVE
Randomized Trial, JAMA 297 (2007) 1883–1891.
[23] M. Drummond, M. Sculpher, G. Torrance, et al., Methods for the Economic Evalua-
tion of Health Care Programmes, Oxford University Press, Oxford, 2005.
[24] J. Parissis, K. Athanasakis, D. Farmakis, N. Boubouchairopoulou, C.Mareti, V. Bistola, I.
Ikonomidis, J. Kyriopoulos, G. Filippatos, J. Lekakis, Determinants of the direct cost of
heart failure hospitalization in a public tertiary hospital, Int. J. Cardiol. 180 (2015)
46–49.
[25] M.S. Nieminen, K. Dickstein, C. Fonseca, J. Magaña Serrano, J. Parissis, F. Fedele, G.
Wikström, P. Agostoni, S. Atar, L. Baholli, D. Brito, J. Comín Colet, I. Èdes, J.E.
Gómez Mesa, V. Gorjup, E. Herrera Garza, J.R. González Juanatey, N. Karanovic, A.
Karavidas, I. Katsytadze, M. Kivikko, S. Matskeplishvili, B. Merkely, F. Morandi, A.
Novoa, F. Oliva, P. Ostadal, A. Pereira-Barretto, P. Pollesello, A. Rudiger, R.H.G.Schwinger, M. Wieser, I. Yavelov, R. Zymliński, The patient perspective: quality of
life in advanced heart failure with frequent hospitalisations, Int. J. Cardiol. 191
(2015) 256–264.
[26] I. Leprán, P. Pollesello, S. Vajda, A. Varró, J.G. Papp, Preconditioning effects of
levosimendan in a rabbit cardiac ischemia-reperfusion model, J. Cardiovasc.
Pharmacol. 48 (4) (2006) 148–152.
[27] J. Levijoki, P. Pollesello, P. Kaheinen, H. Haikala, Improved survival with simendan
after experimental myocardial infarction in rats, Eur. J. Pharmacol. 419 (2–3)
(2001) 243–248.
[28] W. Toller, M. Heringlake, F. Guarracino, L. Algotsson, J. Alvarez, H. Argyriadou, T.
Ben-Gal, V. Černý, B. Cholley, A. Eremenko, J.L. Guerrero-Orriach, K. Järvelä, N.
Karanovic, M. Kivikko, P. Lahtinen, V. Lomivorotov, R.H. Mehta, Š. Mušič, P.
Pollesello, S. Rex, H. Riha, A. Rudiger, M. Salmenperä, L. Szudi, L. Tritapepe, D.
Wyncoll, A. Öwall, Preoperative and perioperative use of levosimendan in cardiac
surgery: European expert opinion, Int. J. Cardiol. 184C (2015) 323–336.
[29] Italian Ministry of Health; ICD9-CM DRG classiﬁcation; table http://www.salute.gov.
it/imgs/C_17_tavole_1_allegati_iitemAllegati_3_ﬁleAllegati_itemFile_8_ﬁle.xls
accessed on June 1, 2015.
[30] Red Española de Costes Hospitalarios (RECH); from the norm AP-GRD 25.0. Page
http://www.osakidetza.euskadi.eus/contenidos/informacion/osk_publicaciones/es_
publi/adjuntos/calidad/ManualAPGRDv.25.0.pdf accessed on June 1, 2015.
[31] Fallpauschalen-Katalog (InEK 2015); http://www.g-drg.de/cms/inek_site_de/
layout/set/einspaltig/G-DRG-System_2015/Fallpauschalen-Katalog/Fallpauschalen-
Katalog_2015; Web page accessed on June 1, 2015.
[32] HUS Palveluhinnasto 2015 OSA 1; page accessed on June 1 2015 http://www.hus.ﬁ/
hus-tietoa/talous/Hinnoittelu/Documents/HUS%20Palveluhinnasto%202015%
20OSA%201.pdf.
[33] State of Israel—Ministry of Health, Tariff and price lists. Web page accessed on June
1, 2015: http://www.health.gov.il/subjects/ﬁnance/taarifon/pages/pricelist.aspx.
[34] C.H. Bergh, B. Andersson, U. Dahlström, K. Forfang, M. Kivikko, T. Sarapohja, B.
Ullman, G. Wikström, Intravenous levosimendan vs. dobutamine in acute decom-
pensated heart failure patients on beta-blockers, Eur. J. Heart Fail. 12 (4) (2010)
404–410.
[35] H. Duygu, F. Ozerkan, S. Nalbantgil, M. Zoghi, A. Akilli, M. Akin, C. Nazli, O. Ergene,
Effect of levosimendan on E/E′ ratio in patients with ischemic heart failure, Int. J.
Cardiol. 123 (2) (2008) 201–203.
[36] H. Duygu, U. Turk, O. Ozdogan, S. Akyuz, B. Kirilmaz, E. Alioglu, R. Gunduz, Y.T.
Bozkaya, C. Turkoglu, S. Payzin, Levosimendan versus dobutamine in heart failure
patients treated chronically with carvedilol, Cardiovasc. Ther. 26 (3) (2008)
182–188.
[37] J.T. Parissis, C. Papadopoulos, M. Nikolaou, V. Bistola, D. Farmakis, I. Paraskevaidis, G.
Filippatos, D. Kremastinos, Effects of levosimendan on quality of life and emotional
stress in advanced heart failure patients, Cardiovasc. Drugs Ther. 21 (4) (2007)
263–268.
[38] A. Trikas, C. Antoniades, G. Latsios, K. Vasiliadou, I. Karamitros, D. Tousoulis, C.
Tentolouris, C. Stefanadis, Long-term effects of levosimendan infusion on inﬂamma-
tory processes and sFas in patients with severe heart failure, Eur. J. Heart Fail. 8 (8)
(2006) 804–809.
